Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session

294 - Baseline CRP predicts severe immune related adverse events

Date

14 Dec 2018

Session

Poster Display session

Presenters

Rik Verheijden

Citation

Annals of Oncology (2018) 29 (suppl_10): x1-x10. 10.1093/annonc/mdy493

Authors

R. Verheijden, K. Suijkerbuijk

Author affiliations

  • Cancer Center, University Medical Center Utrecht, 3508 GA - Utrecht/NL
More

Resources

Abstract 294

Background

The PD-1 inhibitors nivolumab and pembrolizumab are currently widely used as treatment of advanced melanoma. While being tolerated very well by some patients, they cause severe and even fatal immune related adverse events (irAEs) in others. Factors associated with increased risk of toxicity have barely been identified. With the perspective of long-term survival in stage IV disease, and increasing numbers of patients receiving adjuvant immunotherapy in stage III melanoma, being able to predict severe (≥grade 3) toxicity becomes more and more important. In this study, we aimed to assess factors associated with severe irAEs in clinical data and routine peripheral blood tests.

Methods

Patients with advanced (stage III-IV) melanoma, treated with nivolumab or pembrolizumab with at least 3 months follow-up were included. Demographical parameters together with lactate dehydrogenases (LDH), C-reactive protein (CRP), leukocytes, eosinophils, neutrophils and lymphocytes at baseline and at last measurement before toxicity were retrieved retrospectively. IrAEs were graded according to CTCAE 4.03. Non parametric tests were used to assess the difference between groups.

Results

60 patients treated with anti-PD1 monotherapy were included, of whom 7 developed ≥grade 3 irAEs. Median CRP at baseline was significantly higher in patients that experienced severe irAEs (25mg/L) compared to patients who did not (3 mg/L; p = 0,038). Furthermore, in patients with severe irAEs, median eosinophil level at last measurement before toxicity (0,27x109/L) was significantly increased compared to baseline (0,15x109/L; p = 0,047).

Conclusions

Our data indicate that baseline CRP is a potential predictor of severe anti-PD1 induced toxicity. If confirmed in a larger study, CRP could play a role in clinical decision making at the start of treatment. Furthermore, our observation that increase of eosinophils precedes ≥grade 3 toxicity underpins its possible role in the pathogenesis of irAEs and could help identify and treat irAEs at an early stage.

Editorial acknowledgement

Clinical trial identification

Legal entity responsible for the study

University Medical Center Utrecht.

Funding

Has not received any funding.

Disclosure

K. Suijkerbuijk: Consulting/advisory relationship: Bristol-Myers Squibb, MSD; Honoraria (paid to institution): Novartis, Roche. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings